On Monday, Shares of First Majestic Silver Corp (NYSE:AG), subtract -0.36% and closed at $8.20 in the last trading session. The last trading range of the stock ranges between $8.19 and $8.46. The company’s Market capitalization is $1.35 Billion with the total Outstanding Shares of 156.51 million. First Majestic Silver Corp. engages in the acquisition, exploration, development, and production of mineral properties with a focus on silver projects in Mexico. The company owns and operates six silver producing mines, counting the La Encantada Mine, La Parrilla Mine, Del Toro Mine, San Martin Mine, La Guitarra Mine, and Santa Elena Mine. It also holds interests in the Plomosas silver project situated in Sinaloa State; La Luz silver project located in San Luis Potosi State; and Jalisco group of properties located in various mining districts in Jalisco, Mexico. The company was formerly known as First Majestic Resource Corp. and changed its name to First Majestic Silver Corp. in November 2006.
McDonald’s Corporation (NYSE:MCD), jumped 1.11% and closed at $114.71 in the last trading session. The last trading range of the stock ranges between $114.16 and $114.99. The company’s Market capitalization is $97.49 Billion with the total Outstanding Shares of 853.30 million. During the 52-week trading session the minimum price at which share price traded, registered at $101.60 and reached to max level of $131.96. On September 28, 2016, McDonald’s Board of Directors declared a quarterly cash dividend of $0.94 per share of common stock payable on December 15, 2016 to shareholders of record at the close of business on December 1, 2016. This represents a 6% increase over the Company’s previous quarterly dividend and brings the fourth quarter dividend payout to nearly $800 million.
McDonald’s President and Chief Executive Officer Steve Easterbrook said, “I’m encouraged by the meaningful progress we’ve made against our turnaround plan and energized by the opportunities that lie ahead. Recently’s dividend increase reflects the strength and stability of our cash flow and our continued focus on driving long-term value for all stakeholders.”
McDonald’s has raised its dividend each and every year since paying its first dividend in 1976. The new quarterly dividend of $0.94 per share is equivalent to $3.76 annually. In addition, 2016 represents the final year of the Company’s three-year, $30 billion cash return to shareholders target. Through August, the Company returned a cumulative $26 billion and is on track to complete the remaining amount by the end of the year.
On the otherhand Medtronic PLC (NYSE:MDT), jumped 0.24% and closed at $86.17 in the last trading session. The last trading range of the stock ranges between $85.96 and $86.75. The company’s Market capitalization is $119.08 Billion with the total Outstanding Shares of 1.38 billion. During the 52-week trading session the minimum price at which share price traded, registered at $71.03 and reached to max level of $89.27. Medtronic plc (MDT) recently declared positive clinical data for its investigational Avalus(TM) pericardial aortic surgical valve, intended for the treatment of aortic valve disease. Presented at the 30th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting for the first time, results from the PERIGON (PERIcardial SurGical AOrtic Valve ReplacemeNt) Pivotal Trial showed low rates of adverse valve-related events, high survival and improved hemodynamic performance at one year.
One of the leading, most comprehensive and modern data sets of surgical aortic valve replacement (SAVR) patients, the PERIGON Pivotal Trial is a single arm, non-randomized, prospective study of about 1,300 patients from 40 clinical sites across Europe, Canada, Japan and the United States. In the cohort presented at EACTS, outcomes of 270 patients were analyzed at the one-year endpoint. The vast majority (91 percent) of patients were at low mortality risk for open heart surgery (STS<=4 percent), with the remaining 8 percent at intermediate risk (STS=4 to 8 percent) and <1 percent at high risk (STS>=8 percent). At one year, all patients showed low rates of all-cause mortality (3.6 percent) and cardiac death (1.1 percent).
“As surgical aortic valve replacement remains one of the most important treatment options for patients, the one-year outcomes from the PERIGON trial demonstrate how the advanced design elements of Avalus contribute to positive valve performance and clinical outcomes,” saidRobert Klautz, M.D., cardiothoracic surgeon, head of the department of cardiothoracic surgery at the Leiden University Medical Center in The Netherlands, and co-primary investigator of the PERIGON trial and presenter of the one-year results at EACTS. “The value of this large, contemporary dataset is that it allows surgeons to better understand treatment for recently`s SAVR patients, as opposed to data from older studies that may not be as representative.”